Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Oculis OCS-01 DME trial fails
Business clinical trial results

Oculis OCS-01 DME trial fails

Analysis based on 18 articles · First reported May 29, 2026 · Last updated Jun 08, 2026

Sentiment
-60
Attention
4
Articles
18
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The failure of Oculis's OCS-01 eye drops in Phase 3 trials for diabetic macular edema is expected to negatively impact Oculis's stock price due to the loss of a significant potential revenue stream. This event may also affect investor sentiment towards other biopharmaceutical companies with similar drug candidates in early-stage development for DME.

Biotechnology Pharmaceuticals
Event Summary

Oculis announced disappointing topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops in patients with diabetic macular edema (DME). The primary endpoint of improved best corrected visual acuity was not met in either trial, although a secondary endpoint showed a persistent reduction in retinal thickness. Consequently, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME. Oculis's CEO, Riad Sherif, expressed disappointment but affirmed the company's strong financial position and its strategic decision to reallocate resources to other late-stage development programs, including Privosegtor for optic neuropathies and Licaminlimab for dry eye disease.

Key Actions
100 Oculis announced topline results
95 Oculis did not meet endpoint
90 Oculis will not pursue filing United States — Food and Drug Administration
80 Oculis will focus resources
80 Riad Sherif claimed product works
60 Levi & Korsinsky initiated investigation Oculis
Entities Involved
priv
Oculis
Oculis announced that its OCS-01 eye drops failed to meet the primary endpoint in Phase 3 trials for diabetic macular edema (DME), leading to a decision not to pursue FDA regulatory filing for this indication. This negatively impacts Oculis's stock and future revenue expectations for OCS-01 in DME.
Importance 100 Sentiment -70
per
Riad Sherif
As CEO of Oculis, Riad Sherif announced the disappointing Phase 3 trial results for OCS-01 and outlined the company's strategic shift to focus on other late-stage development programs.
Importance 70 Sentiment -50
priv
Levi & Korsinsky
Levi & Korsinsky is a law firm investigating Oculis for potential securities fraud due to misleading statements regarding the OCS-01 DME program, offering legal services to affected shareholders.
Importance 50 Sentiment 20
govactor
United States — Food and Drug Administration
Oculis decided not to pursue an FDA regulatory filing for OCS-01 in DME due to the trial results, meaning the drug will not be available in the United States for this indication.
Importance 30 Sentiment 0
per
Joseph E. Levi
Joseph E. Levi, Esq. is a contact person for Levi & Korsinsky, which is investigating Oculis for potential securities law violations.
Importance 30 Sentiment 0
cnt
United States
The United States was one of several countries where the DIAMOND trials were conducted, indicating its role as a key location for clinical research.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.